Business Wire

DIXA

10.3.2022 11:32:05 CET | Business Wire | Press release

Share
Dixa Leverages $43 Million Double Acquisition of CX Intelligence and Automation Pioneers, Miuros and Solvemate, to Deliver High-value Customer Experiences at Scale

Danish customer support innovator Dixa has today announced the acquisitions of analytics leader Miuros , and automation pioneer Solvemate . Driven by a need amongst service teams to connect to customers with intelligence, empathy, and the right information, the double acquisition is valued at $43 million and strengthens Dixa’s long-term vision to set a new standard in experience and data-driven conversational customer service, giving brands the toolkit they need to utilize data on a new scale for automation, measurement and analytics.

Dixa is used by consumer-facing and digital-first brands to serve customers across multiple channels, touchpoints and experiences from a single screen including social media, chat, voice and messaging apps, enabling an outstanding experience for both customers and agents. With cross-channel prioritization features, powerful routing capabilities, and flexible integrations, Dixa helps brands across the globe deliver value-driven customer experiences at scale, all from a single platform.

Solvemate builds in a powerful self-service layer into the platform that ensures brands can create a painless customer experience with the power of AI to give instant, personal, reliable answers via any customer-facing channel, or funnel requests to the right agent. Its introduction means users can now handle the end-to-end customer journey in a more intelligent, automated and conversational way, while also improving the agent experience through more seamless bot-to-agent handovers.

Miuros was designed to help brands turn customer data into actionable insights with AI-powered analytics, quality assurance and automation. Its addition to the Dixa platform will allow service leaders to harness the power of this technology and gain a better, more comprehensive understanding of the service function. Underpinned by Dixa’s data-rich foundation, service leaders will be able to make stronger, data-informed decisions, such as spotting and acting upon trends in agent productivity and sentiment.

“To create value-driven experiences, brands need a complete platform that leverages data, AI and machine learning to deliver the right knowledge to customers, support agents and internal teams at the right time,” said Mads Fosselius, CEO and co-founder of Dixa. “In being able to draw on our data-rich foundation and existing knowledge base, Elevio, the addition of Miuros and Solvemate will allow service leaders to leverage data on a new scale for automation, measurement and insights from a single platform, setting an entirely new standard in data-driven customer service.”

Dixa’s acquisition rounds out an impressive service offering that also includes a new, bespoke messaging product that delivers rich messaging across web, mobile, and app environments. Dixa Messenger will launch in March 2022, joining native telephony, email, and social messaging support on Dixa’s platform.

“Dixa Messenger is a powerful new service desk for your brand, allowing customer loving teams to create great experiences wherever your customers are,” says Rob Krassowski, Dixa’s VP of Product, “Solvemate and Miuros allow us to take a more data-driven approach to automation and self-service, plus give service agents the tools that they need to create compelling experiences for customers and real business value for their brands.”

Erik Pfannmöller, CEO & Co-founder from Solvemate added: “Powered by smart conversational AI, Solvemate allows brands to create highly personalized chatbot conversations at scale, guiding customers to find answers when they need them. Reducing the number of common, repetitive requests handled by agents means that service teams can focus their expertise where it matters most: solving the more complex cases which require a human touch. By giving consumers faster solutions and taking away noise for agents, we share Dixa’s ambition to service a multiexperience world for delivering unparalleled customer service.”

Benoit Gagnon, CEO & Co-founder from Miuros said: “Dixa is the only platform that can turn a traditional customer service organization into a value creation team by elevating both the agent and customer experience, and we’re delighted to be joining during such an exciting period. Miuros was designed to bring customer service data to life, creating actionable insights to streamline operations, as well as empowering the whole company to create an outstanding customer experience. By adding Miuros’ analytics capabilities, service leaders will now be able to optimize their operations through AI and obtain actionable insights, without needing to stitch together multiple siloed solutions.”

Solvemate, with a global customer base of over 100 brands such as On, JustPark, Sport24, Holidu and CreditPlus, was founded in 2015 by co-founders Erik Pfannmöller, Jürgen Vogel and Christian Blomberg. Miuros, with a global customer base of over 100 mid-market and enterprise brands, including Deezer, Wise, About You, Freenow and Swapfiets, was founded in 2016 by co-founders Benoit Gagnon, Dr. Ricardo De Aldama and Daniele Alfarone. Solvemate and Miuros will continue to service their current customers across platforms in addition to expanding on existing integrations with Dixa.

Dixa has raised $155 million in funding to date with backing from Notion Capital, Project A Ventures, SEED Capital and recently from General Atlantic. The company has offices in Copenhagen, London, Berlin, Paris, Chicago, Tallinn, Kiev, Tel Aviv and Melbourne.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye